For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Sepracor Renamed Sunovion
October 25, 2010
- 1st-Line Japanese Cohort Analysis Data to Be Presented at ASH
October 25, 2010
- Gov't to Create Fund to Subsidize Vaccination against HPV
October 18, 2010
- Sandoz Launches First Ramosetron Generic in Japan
October 18, 2010
- Takeda Ties Up with Envoy to Develop Schizophrenia Drugs
October 18, 2010
- Market for OTC Kampo Medicines to Grow 0.8% to ¥239.4 Bil. in 2010
October 18, 2010
- Ranbaxy Granted 180-Day Exclusivity for Generic Aricept in the US
October 18, 2010
- Asubio Pharma Starts Operation in Kobe
October 18, 2010
- 2-Week Prescription Limit Lifted for Reflex, Remeron
October 18, 2010
- 2 Japanese Scientists Awarded Nobel Prize in Chemistry
October 18, 2010
- BI Initiates PIII for BIBW 2992 for Advanced Breast Cancer
October 18, 2010
- KCI Aims at US$100 Mil. Sales with V.A.C. Therapy System in Japan
October 18, 2010
- Prof. Negishi's Distinction Marks Major Landmark in Teijin's History: President Ohyagi
October 18, 2010
- Kyowa Kirin Begins KW-0761 PIIb for T/NK-Cell Lymphoma
October 18, 2010
- Kyowa Kirin Licenses KW-6356 to Lundbeck
October 18, 2010
- Public-Knowledge Based Applications Recommended for 9 APIs, 10 Indications
October 18, 2010
- LTT Bio-Pharma Starts PI for Inhaled PC-SOD Formulation
October 18, 2010
- NBI, Astellas to Emphasize Long-Lasting Efficacy of Micamlo
October 18, 2010
- Gov't-Industry Dialogue Essential: New Health Minister Hosokawa
October 18, 2010
- Hisamitsu Discontinues Development of HKT-500 in the US
October 18, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…